Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine
Authors:
- 1 June 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 13 (23) , 26682-26693
Abstract
Glioma is one of the most lethal and complex tumors, and thus, an effective drug delivery system must selectively target the tumor sites and release its cargos in a controlled manner. For the first time, we combined chemotherapeutic agent doxorubicin (DOX) and chemosensitizer lonidamine (LND) to synergistically treat glioma. We also designed and prepared multitargeted redox-sensitive liposomes (Lip-SPG) co-modified with glucose and triphenylphosphonium (TPP) to effectively deliver DOX and LND for anti-glioma therapy. The anti-glioma evaluation shows that DOX and LND have a synergistic effect and Lip-SPG could further enhance their cooperation. In vitro, Lip-SPG could increase the cellular uptake and mitochondrial uptake on bEnd.3 cells and C6 cells with multitargeting ability on the brain, tumor, and mitochondria mediated by glucose and TPP. Lip-SPG can also escape from lysosomes before entering the mitochondria. The anti-glioma efficacy in vitro shows that Lip-SPG can inhibit tumor cell proliferation and induce apoptosis. In addition, Lip-SPG have a remarkable interference to mitochondria, such as reducing intracellular ATP production, inducing ROS generation, and promoting mitochondrial membrane potential depolarization. Furthermore, in vivo, the introduction of PEGylation via glutathione-sensitive disulfide bonds endows Lip-SPG with favorable pharmacokinetic properties, brain targeting ability, low toxicity to normal tissues, and great anti-glioma efficacy with the survival time extended from 19 to 39 days. In conclusion, Lip-SPG are an effective delivery system for synergistically treating glioma with DOX and LND.Keywords
Funding Information
- Science and Technology Department of Sichuan Province (2018JY0537, 2020YJ0221)
- National Natural Science Foundation of China (81573286, 81773577, 81903448)
- Sichuan Youth Science and Technology Innovation Research Team Funding (2016TD0001)
This publication has 36 references indexed in Scilit:
- Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivoJournal of Controlled Release, 2012
- Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targetingInternational Journal of Nanomedicine, 2012
- Design, synthesis and preliminary bio-evaluation of glucose–cholesterol derivatives as ligands for brain targeting liposomesChinese Chemical Letters, 2011
- Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseasesNeurobiology of Disease, 2010
- Malignant Gliomas in Adults2010
- Subcellular targeting strategies for drug design and deliveryNature Reviews Drug Discovery, 2010
- Multifunctional and stimuli-sensitive pharmaceutical nanocarriersEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Organelle-Targeted Nanocarriers: Specific Delivery of Liposomal Ceramide to Mitochondria Enhances Its Cytotoxicity in Vitro and in VivoNano Letters, 2008
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006
- Structure and Function of Sinusoidal Lining Cells in the LiverToxicologic Pathology, 1996